US Pharma MarketingThe post Argo points to swelling disorder drug’s differentiated profile on Phase II success appeared first on Clinical Trials Arena.
Argo points to swelling disorder drug’s differentiated profile on Phase II success
This mid-stage success could poise Argo to compete with Takeda’s blockbuster drug Takhzyro on the HAE market. This mid-stage success could poise Argo to compete with Takeda’s blockbuster drug Takhzyro on the HAE market, which is becoming highly competitive. Argo hopes BW-20805 can offer as a differentiated preventative therapy for HAE based on its dosing schedule. Credit: Velimir Zeland / Shutterstock.com. Argo Biopharmaceutical has debuted new data from a Phase II study on its preventative therapy, BW-20805 in hereditary angioedema (HAE), that the company says highlights its “differentiated clinical profile” in this condition. Through a multi-national, open-label trial (NCT06846398), Argo…
This mid-stage success could poise Argo to compete with Takeda’s blockbuster drug Takhzyro on the HAE market.
Source: Clinical Trials Arena